Report Company Directory

Cogna Educacao S.A.

• H&E Major Pulse "Stock Movers: short shift from FLRY to ODPV; Ms. Lenise..." by UBS AG
• Itaú BBA on Cogna: Cogna Announces Medical School Acquisition for BRL 0.9 million per Seat by Itau
• Cogna Educacao SA "Deep dive into 2Q25 receivables quality" (Neutral) Salles by UBS AG
• First Read: Cogna Educacao SA "Solid, but expected Q2 with financial result..." by UBS AG
• H&E Major Pulse "Stock Movers: short interests raise ahead of 2Q results;..." by UBS AG
• H&E Major Pulse "RDOR CEO interview (+); YDUQS' plans with new CEO (+);..." by UBS AG
• H&E Major Pulse "Positive sector reaction on new Ministry of Health's..." by UBS AG
• Itaú BBA on Education: 2Q25 Earnings Preview by Itau
• H&E Major Pulse "Shrunken PNLD: ~3% impact on COGN revenue; New..." by UBS AG
• Cogna Educacao SA "2Q25 preview: Positive growth print, flattish margins,..." by UBS AG

COGNA EDUCACAO SA

Cognex Corporation

• Cognex Corp (CGNX US) by HSBC
• Cognex Corp "COGNizant of broadening end market momentum. Raising PT to $58." by UBS AG
• Revenge of the Cognoids by BNP Paribas Exane
• First Read: Cognex Corp "6% operating beat on margin execution. 3Q guidance..." by UBS AG
• Q2 sales mostly in line, margins beat; Q3 sales and margins guided ahead by BNP Paribas Exane
• Automation whiplash - the setup into Q225 by BNP Paribas Exane
• Sustainable Transition "転換点 - 自信が戻りつつある" Glover by UBS AG
• Non-Residential Construction Update "Pharma/Life Science: A Cure for..." by UBS AG
• Sustainable Transition "Points of Inflection - Confidence Returning" Glover by UBS AG
• ESG Express "Building Blocks of Decarb" Gershuni by UBS AG

Cognition Holdings

• Ford Equity International Rating and Forecast Report by Ford Equity Research

COGNITION THERAPEUTICS INC

• Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease by GlobeNewsWire
• Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs by GlobeNewsWire
• Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease by GlobeNewsWire
• Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease by GlobeNewsWire
• Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC by GlobeNewsWire
• Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease by GlobeNewsWire
• Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target by GlobeNewsWire
• Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB) by GlobeNewsWire
• Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies by GlobeNewsWire
• Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies by GlobeNewsWire